# Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors

> **NCT00661414** · PHASE1 · COMPLETED · sponsor: **Lpath, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **BIOLOGICAL:** ASONEP (sonepcizumab/LT1009)

## Key facts

- **NCT ID:** NCT00661414
- **Lead sponsor:** Lpath, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2012-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00661414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00661414, "Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00661414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*